{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/RXRX/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T07:59:16.521Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1255,"canonical_name":"RECURSION PHARMACEUTICALS, INC.","cik":"0001601830","uei":null,"lei":null,"duns":null,"ticker":"RXRX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":87,"clinical":2},"count":89,"timeline":[{"ts":"2026-07-21","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":100000,"usd_value":304263,"security_title":"Class A","approx_sale_date":"2026-07-21","accession_number":"0001959173-26-005307","importance":40.060852508},{"ts":"2026-07-21","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-21","url_slug":"/sec/cik-0001601830/144/0001959173-26-005307","accession_number":"0001959173-26-005307","importance":30},{"ts":"2026-07-20","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":100000,"usd_value":289766,"security_title":"Class A","approx_sale_date":"2026-07-20","accession_number":"0001959173-26-005291","importance":40.057953274},{"ts":"2026-07-20","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-20","url_slug":"/sec/cik-0001601830/144/0001959173-26-005291","accession_number":"0001959173-26-005291","importance":30},{"ts":"2026-07-17","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":100000,"usd_value":296726,"security_title":"Class A","approx_sale_date":"2026-07-17","accession_number":"0001959173-26-005272","importance":40.05934518},{"ts":"2026-07-17","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-17","url_slug":"/sec/cik-0001601830/144/0001959173-26-005272","accession_number":"0001959173-26-005272","importance":30},{"ts":"2026-07-16","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":100000,"usd_value":311065,"security_title":"Class A","approx_sale_date":"2026-07-16","accession_number":"0001959173-26-005257","importance":40.062212974},{"ts":"2026-07-16","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-16","url_slug":"/sec/cik-0001601830/144/0001959173-26-005257","accession_number":"0001959173-26-005257","importance":30},{"ts":"2026-07-15","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":123334,"usd_value":410283,"security_title":"Class A","approx_sale_date":"2026-07-15","accession_number":"0001959173-26-005236","importance":40.08205652},{"ts":"2026-07-15","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-15","url_slug":"/sec/cik-0001601830/144/0001959173-26-005236","accession_number":"0001959173-26-005236","importance":30},{"ts":"2026-07-14","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":100000,"usd_value":330473,"security_title":"Class A","approx_sale_date":"2026-07-14","accession_number":"0001959173-26-005224","importance":40.066094536},{"ts":"2026-07-14","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-14","url_slug":"/sec/cik-0001601830/144/0001959173-26-005224","accession_number":"0001959173-26-005224","importance":30},{"ts":"2026-07-13","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":100000,"usd_value":343048,"security_title":"Class A","approx_sale_date":"2026-07-13","accession_number":"0001959173-26-005213","importance":40.06860962},{"ts":"2026-07-13","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-13","url_slug":"/sec/cik-0001601830/144/0001959173-26-005213","accession_number":"0001959173-26-005213","importance":30},{"ts":"2026-07-09","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":286000,"usd_value":1085716,"security_title":"Class A","approx_sale_date":"2026-07-09","accession_number":"0001959173-26-005183","importance":40.217143258},{"ts":"2026-07-09","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-09","url_slug":"/sec/cik-0001601830/144/0001959173-26-005183","accession_number":"0001959173-26-005183","importance":30},{"ts":"2026-07-09","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-07-09","url_slug":"/sec/cik-0001601830/4/0001856094-26-000011","accession_number":"0001856094-26-000011","importance":30},{"ts":"2026-07-08","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":200000,"usd_value":737694,"security_title":"Class A","approx_sale_date":"2026-07-08","accession_number":"0001959173-26-005163","importance":40.147538816},{"ts":"2026-07-08","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-08","url_slug":"/sec/cik-0001601830/144/0001959173-26-005163","accession_number":"0001959173-26-005163","importance":30},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":250000,"usd_value":987500,"security_title":"Class A","approx_sale_date":"2026-07-07","accession_number":"0001959173-26-005141","importance":40.1975},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Borgeson Blake","title":"Director","shares":40000,"usd_value":158500,"security_title":"Class A","approx_sale_date":"2026-07-07","accession_number":"0001959173-26-005138","importance":40.0317},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Borgeson Blake","title":null,"shares":40000,"price_per_share":3.9625,"usd_value":158500,"security_title":"Class A Common Stock","importance":35.1585},{"ts":"2026-07-07","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-07","url_slug":"/sec/cik-0001601830/144/0001959173-26-005138","accession_number":"0001959173-26-005138","importance":30},{"ts":"2026-07-07","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-07","url_slug":"/sec/cik-0001601830/144/0001959173-26-005141","accession_number":"0001959173-26-005141","importance":30},{"ts":"2026-07-06","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":100000,"usd_value":378000,"security_title":"Class A","approx_sale_date":"2026-07-06","accession_number":"0001959173-26-005116","importance":40.0756},{"ts":"2026-07-06","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-06","url_slug":"/sec/cik-0001601830/144/0001959173-26-005116","accession_number":"0001959173-26-005116","importance":30},{"ts":"2026-07-02","kind":"sec.form144","reporter":"Gibson Christopher","title":"Former Director","shares":100000,"usd_value":374500,"security_title":"Class A","approx_sale_date":"2026-07-02","accession_number":"0001959173-26-005052","importance":40.0749},{"ts":"2026-07-02","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-02","url_slug":"/sec/cik-0001601830/144/0001959173-26-005052","accession_number":"0001959173-26-005052","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-07-02","url_slug":"/sec/cik-0001601830/4/0001601830-26-000091","accession_number":"0001601830-26-000091","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-07-02","url_slug":"/sec/cik-0001601830/4/0001601830-26-000092","accession_number":"0001601830-26-000092","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-07-01","url_slug":"/sec/cik-0001601830/144/0001959173-26-005037","accession_number":"0001959173-26-005037","importance":30},{"ts":"2026-07-01","kind":"sec.insider.a","reporter":"Li Dean Y","title":null,"shares":3747,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-07-01","kind":"sec.insider.a","reporter":"Dar Zavain","title":null,"shares":5109,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-22","url_slug":"/sec/cik-0001601830/4/0001601830-26-000082","accession_number":"0001601830-26-000082","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-22","url_slug":"/sec/cik-0001601830/4/0001601830-26-000083","accession_number":"0001601830-26-000083","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-22","url_slug":"/sec/cik-0001601830/4/0001601830-26-000084","accession_number":"0001601830-26-000084","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-22","url_slug":"/sec/cik-0001601830/4/0001601830-26-000085","accession_number":"0001601830-26-000085","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-22","url_slug":"/sec/cik-0001601830/4/0001601830-26-000086","accession_number":"0001601830-26-000086","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-22","url_slug":"/sec/cik-0001601830/4/0001601830-26-000088","accession_number":"0001601830-26-000088","importance":30},{"ts":"2026-06-18","kind":"sec.form144","reporter":"Gibson Christopher","title":"Director","shares":300440,"usd_value":962341,"security_title":"Class A","approx_sale_date":"2026-06-18","accession_number":"0001959173-26-004782","importance":40.192468258},{"ts":"2026-06-18","kind":"sec.form144","reporter":"Gibson Christopher","title":"Director","shares":40000,"usd_value":127200,"security_title":"Class A","approx_sale_date":"2026-06-18","accession_number":"0001959173-26-004757","importance":40.02544},{"ts":"2026-06-18","kind":"sec.form144","reporter":"Bumpus Namandje","title":"Director","shares":3963,"usd_value":12602,"security_title":"Class A","approx_sale_date":"2026-06-18","accession_number":"0001959173-26-004759","importance":40.002520468},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Bumpus Namandje","title":null,"shares":3963,"price_per_share":3.18,"usd_value":12602,"security_title":"Class A Common Stock","importance":35.01260234},{"ts":"2026-06-18","kind":"sec.filing","form_type":"8-K","title":"8-K — RECURSION PHARMACEUTICALS, INC. — 2026-06-18","url_slug":"/sec/cik-0001601830/8-k/0001601830-26-000080","accession_number":"0001601830-26-000080","importance":35},{"ts":"2026-06-18","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-06-18","url_slug":"/sec/cik-0001601830/144/0001959173-26-004757","accession_number":"0001959173-26-004757","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-06-18","url_slug":"/sec/cik-0001601830/144/0001959173-26-004759","accession_number":"0001959173-26-004759","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-06-18","url_slug":"/sec/cik-0001601830/144/0001959173-26-004782","accession_number":"0001959173-26-004782","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-17","url_slug":"/sec/cik-0001601830/4/0001712276-26-000007","accession_number":"0001712276-26-000007","importance":30},{"ts":"2026-06-17","kind":"sec.insider.a","reporter":"HERSHBERG ROBERT","title":null,"shares":88424,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.insider.a","reporter":"Bumpus Namandje","title":null,"shares":88424,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.insider.a","reporter":"Li Dean Y","title":null,"shares":88424,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.insider.a","reporter":"Dar Zavain","title":null,"shares":88424,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.insider.a","reporter":"Sun Elaine D","title":null,"shares":88424,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.insider.a","reporter":"Michor Franziska","title":null,"shares":88424,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.insider.a","reporter":"Borgeson Blake","title":null,"shares":88424,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-15","kind":"sec.insider.f","reporter":"Taylor Ben R","title":"Chief Financial Officer","shares":5396,"price_per_share":3.15,"usd_value":16997,"security_title":"Class A Common Stock","importance":15.0169974},{"ts":"2026-06-05","kind":"sec.form144","reporter":"Gibson Christopher","title":"Director","shares":40000,"usd_value":144800,"security_title":"Class A","approx_sale_date":"2026-06-05","accession_number":"0001959173-26-004369","importance":40.02896},{"ts":"2026-06-05","kind":"sec.form144","reporter":"Najat Khan","title":"Officer","shares":23588,"usd_value":84459,"security_title":"Common","approx_sale_date":"2026-06-05","accession_number":"0001628280-26-041114","importance":40.01689184},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"Gibson Christopher","title":null,"shares":40000,"price_per_share":3.62,"usd_value":144800,"security_title":"Class A Common Stock","importance":35.1448},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"Khan Najat","title":"CEO and President","shares":23588,"price_per_share":3.5806,"usd_value":84459,"security_title":"Class A Common Stock","importance":35.0844591928},{"ts":"2026-06-05","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-06-05","url_slug":"/sec/cik-0001601830/144/0001628280-26-041114","accession_number":"0001628280-26-041114","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-06-05","url_slug":"/sec/cik-0001601830/144/0001959173-26-004369","accession_number":"0001959173-26-004369","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-05","url_slug":"/sec/cik-0001601830/4/0001856369-26-000023","accession_number":"0001856369-26-000023","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-05","url_slug":"/sec/cik-0001601830/4/0002020969-26-000004","accession_number":"0002020969-26-000004","importance":30},{"ts":"2026-06-05","kind":"sec.insider.c","reporter":"Gibson Christopher","title":null,"shares":40000,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-04","url_slug":"/sec/cik-0001601830/4/0001856094-26-000008","accession_number":"0001856094-26-000008","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-06-04","url_slug":"/sec/cik-0001601830/4/0002060594-26-000003","accession_number":"0002060594-26-000003","importance":30},{"ts":"2026-06-03","kind":"sec.form144","reporter":"Bumpus Namandje","title":"Director","shares":4386,"usd_value":15526,"security_title":"Class A","approx_sale_date":"2026-06-03","accession_number":"0001959173-26-004290","importance":40.003105288},{"ts":"2026-06-03","kind":"sec.insider.s","reporter":"Bumpus Namandje","title":null,"shares":4386,"price_per_share":3.54,"usd_value":15526,"security_title":"Class A Common Stock","importance":35.01552644},{"ts":"2026-06-03","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-06-03","url_slug":"/sec/cik-0001601830/144/0001959173-26-004290","accession_number":"0001959173-26-004290","importance":30},{"ts":"2026-06-02","kind":"sec.form144","reporter":"Borgeson Blake","title":"Director","shares":30000,"usd_value":110400,"security_title":"Class A","approx_sale_date":"2026-06-02","accession_number":"0001959173-26-004239","importance":40.02208},{"ts":"2026-06-02","kind":"sec.insider.s","reporter":"Borgeson Blake","title":null,"shares":30000,"price_per_share":3.68,"usd_value":110400,"security_title":"Class A Common Stock","importance":35.1104},{"ts":"2026-06-02","kind":"sec.filing","form_type":"144","title":"144 — RECURSION PHARMACEUTICALS, INC. — 2026-06-02","url_slug":"/sec/cik-0001601830/144/0001959173-26-004239","accession_number":"0001959173-26-004239","importance":30},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-05-19","url_slug":"/sec/cik-0001601830/4/0002006495-26-000010","accession_number":"0002006495-26-000010","importance":30},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-05-19","url_slug":"/sec/cik-0001601830/4/0002020969-26-000002","accession_number":"0002020969-26-000002","importance":30},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-05-19","url_slug":"/sec/cik-0001601830/4/0001712276-26-000005","accession_number":"0001712276-26-000005","importance":30},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-05-19","url_slug":"/sec/cik-0001601830/4/0001856369-26-000017","accession_number":"0001856369-26-000017","importance":30},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Khan Najat","title":"CEO and President","shares":62701,"price_per_share":3.04,"usd_value":190611,"security_title":"Class A Common Stock","importance":15.19061104},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Hallett David","title":"Chief Scientific Officer","shares":26657,"price_per_share":3.04,"usd_value":81037,"security_title":"Class A Common Stock","importance":15.08103728},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Taylor Ben R","title":"Chief Financial Officer","shares":25018,"price_per_share":3.04,"usd_value":76055,"security_title":"Class A Common Stock","importance":15.07605472},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Gibson Christopher","title":null,"shares":22821,"price_per_share":3.04,"usd_value":69376,"security_title":"Class A Common Stock","importance":15.06937584},{"ts":"2026-05-12","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — RECURSION PHARMACEUTICALS, INC. — 2026-05-12","url_slug":"/sec/cik-0001601830/schedule-13g/0000093751-26-000285","accession_number":"0000093751-26-000285","importance":55},{"ts":"2026-05-12","kind":"sec.13dg","reporter":"RECURSION PHARMACEUTICALS, INC.","shares":28490638,"percent_of_class":5.5,"security_title":"SCHEDULE 13G","accession_number":"0000093751-26-000285","excerpt":null,"importance":55},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Recursion Pharmaceuticals Inc.","title":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06678659","excerpt":"[\"Unresectable\",\"Locally Advanced\",\"Metastatic Cancers\",\"Relapsed/Refractory Lymphomas\"]","importance":45},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — RECURSION PHARMACEUTICALS, INC. — 2026-05-08","url_slug":"/sec/cik-0001601830/4/0001856369-26-000015","accession_number":"0001856369-26-000015","importance":30},{"ts":"2026-05-07","kind":"sec.insider.s","reporter":"Gibson Christopher","title":null,"shares":40000,"price_per_share":3.37,"usd_value":134800,"security_title":"Class A Common Stock","importance":35.1348},{"ts":"2026-05-07","kind":"sec.insider.c","reporter":"Gibson Christopher","title":null,"shares":60000,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-05-07","kind":"sec.insider.g","reporter":"Gibson Christopher","title":null,"shares":20000,"price_per_share":0,"usd_value":0,"security_title":"Class A Common Stock","importance":15},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Recursion Pharmaceuticals Inc.","title":"Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05552755","excerpt":"[\"Familial Adenomatous Polyposis\"]","importance":45}]}